Aug. 23, 2023 – Since the FDA approved once-weekly semaglutide injection in 2021 for chronic weight management for adults with obesity or overweight with at least one weight-related condition, a multibillion-dollar market for anti-obesity medications has followed. Injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk) and its counterpart semaglutide 1 mg (Ozempic), approved to treat type 2 diabetes, are associated with weight loss of as much as 15% to 20% for some patients. The GLP-1 receptor agonists now dominate headlines — and celebrity weight loss speculation — in the mainstream press.
ONE STEP WONDER – Nov. 13, 2024 - Weight loss drugs such as Ozempic and…
ALWAYS WITH YOU – Nov. 2, 2024 - Archaeologists have uncovered a previously unknown effect…
TURN OFF CNN – Nov. 7, 2024 - At Toshikazu Kawaguchi’s book signings, it’s not…
86ed AGAIN? – NOV. 4, 2024 - Two previous rounds of employee cuts in September…
BY A NOSE – Nov. 5, 2024 - Thoroughbred owner and recovering alcoholic Gino Roncelli…
VIDEO – NO VALUE AT ALL – Nov. 4, 2024 - It all started innocently…